Results 131 to 140 of about 6,115 (159)
Some of the next articles are maybe not open access.
Mesalamine Foam EnemaVersusMesalamine Liquid Enema in Active Left-Sided Ulcerative Colitis
The American Journal of Gastroenterology, 2008To determine in a noninferiority study whether mesalamine foam is as effective as mesalamine liquid enema for inducing clinical remission in patients with active left-sided ulcerative colitis (UC).In a multicenter investigator-blind trial, 375 patients with mild-to-moderate UC were randomized to receive mesalamine foam 1 g/80 mL/day or mesalamine ...
Cortot, Antoine +15 more
openaire +3 more sources
Connecticut medicine, 2010
Lung toxicity associated with 5-aminosalicylate (5-ASA) agents is very rare. We report the case of a 48-year-old man with ulcerative colitis who developed progressive shortness of breath while taking oral mesalamine. Chest imaging revealed a ground glass appearance in patchy areas distributed throughout the lung. He had a restrictive ventilatory defect
Neha, Jain +2 more
openaire +1 more source
Lung toxicity associated with 5-aminosalicylate (5-ASA) agents is very rare. We report the case of a 48-year-old man with ulcerative colitis who developed progressive shortness of breath while taking oral mesalamine. Chest imaging revealed a ground glass appearance in patchy areas distributed throughout the lung. He had a restrictive ventilatory defect
Neha, Jain +2 more
openaire +1 more source
Reviews in gastroenterological disorders, 2006
Most current drug delivery systems in the treatment of ulcerative colitis and Crohn's disease release the active drug at the least effective location for treatment. The pharmaceutical industry has been developing different delivery systems for Multi-Matrix System (MMX) mesalamine for the treatment of Crohn's disease and ulcerative colitis. The new oral
openaire +1 more source
Most current drug delivery systems in the treatment of ulcerative colitis and Crohn's disease release the active drug at the least effective location for treatment. The pharmaceutical industry has been developing different delivery systems for Multi-Matrix System (MMX) mesalamine for the treatment of Crohn's disease and ulcerative colitis. The new oral
openaire +1 more source
Headache During Mesalamine Therapy: A Case Report of Mesalamine-Induced Pseudotumor Cerebri
Journal of Pediatric Gastroenterology and Nutrition, 2001D, Rottembourg +5 more
openaire +2 more sources
Mesalamine-induced myocarditis
Medicina Clínica (English Edition), 2016Juan Carlos Querol-Fernández +1 more
openaire +1 more source